神经退行性疾病中多巴胺能神经传递的影像学检查
本文综述黑质纹状体通路、纹状体受体及多巴胺释放影像在帕金森病(PD)和路易体痴呆等神经退行性疾病临床实践与研究中的作用。黑质纹状体通路影像对检测黑质纹状体变性具有高诊断准确性,尤其适用于临床不确定的帕金森综合征患者;纹状体多巴胺D2/3受体影像不再推荐用于帕金森病的鉴别诊断。欧洲药品管理局已将多巴胺转运体影像认定为早期PD临床试验的富集生物标志物。
要点
- 黑质纹状体通路影像对PD和路易体痴呆等黑质纹状体变性疾病的诊断准确性高。
- 纹状体多巴胺D2/3受体影像不再推荐用于帕金森病的临床鉴别诊断。
- 欧洲药品管理局已将多巴胺转运体影像认定为早期PD临床试验的富集生物标志物。
核心结论
- 黑质纹状体通路影像在临床实践和研究中起重要作用,对检测PD和路易体痴呆等疾病的黑质纹状体变性具有高诊断准确性,尤其在临床不确定的帕金森综合征患者中。
- 纹状体多巴胺D2/3受体影像不再推荐用于帕金森病的临床鉴别诊断。
- 欧洲药品管理局已将多巴胺转运体影像认定为早期PD临床试验的富集生物标志物,并将应用于未来试验。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 黑质纹状体通路影像对PD和路易体痴呆等以黑质纹状体变性为特征的疾病具有高诊断准确性,在临床不确定的帕金森综合征患者中更具临床重要性。
- 纹状体多巴胺D2/3受体影像不再推荐用于帕金森病的临床鉴别诊断。
- 突触前多巴胺能系统影像用于研究神经退行性疾病临床前和运动前期的黑质纹状体变性程度以及PD亚型。
- 突触后多巴胺D2/3受体影像用于研究PD冲动控制障碍的神经元基础,以及通过测量内源性多巴胺释放来研究PD治疗中的运动并发症。
- 对神经黑色素敏感的MRI等新型MRI序列是研究活体黑质纹状体变性的有前景的新工具。
关键数值与推荐
- 欧洲药品管理局已将多巴胺转运体影像认定为早期PD临床试验的富集生物标志物。
临床怎么用
- 黑质纹状体通路影像可用于检测PD和路易体痴呆等疾病的黑质纹状体变性,尤其在临床不确定的帕金森综合征患者中具有高诊断准确性。
- 纹状体多巴胺D2/3受体影像不再推荐用于帕金森病的临床鉴别诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging of dopaminergic transmission in neurodegenerative disorders such as Parkinson disease (PD) or dementia with Lewy bodies plays a major role in clinical practice and in clinical research. We here review the role of imaging of the nigrostriatal pathway, as well as of striatal receptors and dopamine release, in common neurodegenerative disorders in clinical practice and research. Imaging of the nigrostriatal pathway has a high diagnostic accuracy to detect nigrostriatal degeneration in disorders characterized by nigrostriatal degeneration, such as PD and dementia with Lewy bodies, and disorders of more clinical importance, namely in patients with clinically uncertain parkinsonism. Imaging of striatal dopamine D2/3 receptors is not recommended for the differential diagnosis of parkinsonian disorders in clinical practice anymore. Regarding research, recently the European Medicines Agency has qualified dopamine transporter imaging as an enrichment biomarker for clinical trials in early PD, which underlines the high diagnostic accuracy of this imaging tool and will be implemented in future trials. Also, imaging of the presynaptic dopaminergic system plays a major role in, for example, examining the extent of nigrostriatal degeneration in preclinical and premotor phases of neurodegenerative disorders and to examine subtypes of PD. Also, imaging of postsynaptic dopamine D2/3 receptors plays a role in studying, for example, the neuronal substrate of impulse control disorders in PD, as well as in measuring endogenous dopamine release to examine, for example, motor complications in the treatment of PD. Finally, novel MRI sequences as neuromelanin-sensitive MRI are promising new tools to study nigrostriatal degeneration in vivo.
引用
- Wallert ED, van de Giessen E, Knol RJJ, et al. Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders. J Nucl Med. 2022. PMID: 35649651. doi:10.2967/jnumed.121.263197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。